GlassScriptPhysician profile
Susan A Goode
NPI 1982755294
$1,900.28
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $658 · 2022: $533 · 2023: $544 · 2024: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $357.47 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $281.23 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.58 | 2022-2024 | |
| Pfizer INC. | $165.68 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.77 | 2021-2023 | Jardiance |
| Mylan Specialty L.P. | $119.48 | 2021-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.54 | 2023-2024 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $84.11 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $80.22 | 2022-2023 | Belsomra, Verquvo |
| Avanir Pharmaceuticals, INC. | $70.39 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $68.51 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $52.72 | 2021-2023 | Farxiga |
| Lundbeck LLC | $46.95 | 2023 | Rexulti |
| Lilly USA, LLC | $34.47 | 2023 | Jardiance |
| Exact Sciences Corporation | $21.59 | 2023 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.56 | 2024 | |
| Eisai INC. | $18.51 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.03 | 2022 | |
| Amarin Pharma, INC. | $15.68 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.79 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Goode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.